Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting
Shots:
- In a post-hoc- sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight "off" time and time to morning "on" time compared to entacapone in patients with PD with motor fluctuations
- The new P-III post-hoc sub-group analysis demonstrated that long-term treatment with Ongentys when used as an add-on therapy reduced "On" time with troublesome dyskinesia and increased good "On" time without troublesome dyskinesia in patients with PD with motor fluctuations
- Long term use of therapy leads to a reduction in the patient's average daily levodopa dosage requirement. Ongentys (qd- PO) is a selective and reversible COMT inhibitor and has received the US FDA’s approval as an add-on treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes
Ref: PRN | Image: Neurocrine
Click here to read the full press release
Tags
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
